| Literature DB >> 23365676 |
Pavel Strnad1, Guido von Figura, Regina Gruss, Katja-Marlen Jareis, Adolf Stiehl, Hasan Kulaksiz.
Abstract
BACKGROUND AND STUDY AIMS: Bile stones represent a highly prevalent condition and abnormalities of the biliary tree predispose to stone recurrence due to development of biliary stasis. In our study, we assessed the importance of an altered bile duct course for stone formation. PATIENTS AND METHODS: 1,307 patients with choledocholithiasis in the absence of any associated hepatobiliary disease who underwent endoscopic retrograde cholangiopancreatography (ERCP) between 2002 and 2009 were analysed. The angle enclosed between the horizontal portion of the common bile duct (CBD) and the horizontal plane was measured (angle α). Oblique common bile duct (OCBD) was defined as a CBD with angle α < 45°.Entities:
Mesh:
Year: 2013 PMID: 23365676 PMCID: PMC3554756 DOI: 10.1371/journal.pone.0054601
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Characterisation of the oblique common bile duct syndrome.
Schematics (A,C) and radiographs (B,D) depict the morphology of “normal” (A,B) and “oblique” bile ducts (C,D). Angle α was defined as the angle enclosed between the horizontal portion of the bile duct and the horizontal plane. H, porta hepatis; P, papilla Vateri.
Prior medical history.
| “Oblique” CBD | Controls | |
| Prior cholecystectomy (n), yes/no | 56/40 | 42/58 |
| Type of cholecystectomy (n), laparoscopic/open | 26/41 | 49/30 |
|
| ||
|
| ||
| Obesity-BMI>30 kg/m2 (n), yes/no | 24/79 | 30/74 |
| High blood pressure (n), yes/no | 55/48 | 56/48 |
| Diabetes mellitus | 24/79 | 14/90 |
| Hyperlipoproteinemia | 17/86 | 12/92 |
|
| ||
| Hematologic disorders (n), yes/no | 7/96 | 2/102 |
| Heart disease (n), yes/no | 37/66 | 32/72 |
| Vascular disorders (thrombembolic, aneurysms etc.) (n), yes/no | 13/90 | 5/99 |
|
| ||
| Gastroesophageal reflux disease (n), yes/no | 5/98 | 11/93 |
| Gastric disorders (ulcers, gastritis) (n), yes/no | 17/86 | 19/85 |
| Bowel disorders (n), yes/no | 11/92 | 6/98 |
|
| ||
| COPD, Asthma (n), yes/no | 7/96 | 8/96 |
|
| ||
| Chronic kidney disease (n), yes/no | 15/88 | 9/96 |
|
| ||
| Stroke (n), yes/no | 6/97 | 2/102 |
| Psychiatric disorders (n), yes/no | 12/91 | 5/99 |
|
| ||
| None (n), yes/no | 75/28 | 87/17 |
| Common bile duct surgery (n), yes/no | 8/95 | 0/104 |
| Colorectal surgery (n), yes/no | 5/98 | 5/99 |
| Hysterectomy (n), yes/no | 5/98 | 4/100 |
| Gastric surgery (n), yes/no | 3/100 | 0/104 |
| Nephrectomy (n), yes/no | 1/102 | 1/103 |
| Hepaticojejunostomy (n), yes/no | 3/100 | 0/104 |
BMI: body mass index; CBD: common bile duct; COPD: chronic obstructive pulmonary disease.
p = 0.02;
p = 0.005;
p = 0.05;
p = 0.003;
ERCP findings.
| ERCP findings | “Oblique” CBD | Controls |
| Common bile duct stones (n),yes/no | 103/0 | 104/0 |
| Acute cholangitis (n), yes/no | 42/61 | 31/73 |
| Biliary pancreatitis (n), yes/no | 21/82 | 23/81 |
| Chronic cholangitis (n), yes/no | 4/99 | 1/103 |
| Biliary fistula (n), yes/no | 5/98 | 0/104 |
| Chronic pancreatitis (n), yes/no | 7/96 | 1/103 |
| Hepatopathy (n), yes/no | 4/99 | 3/101 |
| Papillary stenosis/−sclerosis (n),yes/no | 4/99 | 0/104 |
p = 0.03;
p = 0.04.
Lab values before and after endoscopic retrograde cholangiopancreatography.
| AP (U/l) | GGT (U/l) | Bili (µmol/l) | AST (U/l) | ALT (U/l) | CRP (mg/l) | |||||||
| OB | Co | OB | Co | OB | Co | OB | Co | OB | Co | OB | Co | |
|
| ||||||||||||
| >3 mo | 99 | 82 | 29 | 18 | 11 | 10 | 18 | 15 | 16 | 16 | 3 | 7 |
| 1–12 wk | 142 | 96 | 72 | 28 | 19 | 8 | 45 | 20 | 31 | 20 | 26 | 8 |
| 4–7d | 163 | 134 | 188 | 269 | 13 | 20 | 34 | 57 | 36 | 77 | 15 | 25 |
| 1–2d | 189 | 173 | 327 | 280 | 30 | 32 | 86 | 119 | 76 | 185 | 14 | 16 |
|
| ||||||||||||
| 201 | 157 | 272 | 364 | 54 | 34 | 80 | 92 | 98 | 190 | 91 | 27 | |
|
| ||||||||||||
| 1d | 195 | 152 | 277 | 375 | 37 | 35 | 76 | 77 | 99 | 182 | 59 | 56 |
| 2d | 162 | 100 | 292 | 279 | 49 | 19 | 65 | 63 | 75 | 137 | 105 | 63 |
| 3d | 168 | 135 | 219 | 266 | 22 | 21 | 32 | 34 | 46 | 94 | 35 | 60 |
| 4–7d | 152 | 146 | 189 | 224 | 17 | 12 | 38 | 33 | 39 | 61 | 26 | 32 |
| 1–12 wk | 99 | 82 | 83 | 60 | 9 | 9 | 22 | 24 | 21 | 31 | 11 | 20 |
| >3 mo | 91 | 75 | 42 | 24 | 10 | 8 | 25 | 22 | 17 | 20 | 14 | 6 |
Median values are shown. Calculation of statistical significance is based on a two-tailed Mann-U-Whitney test.
AP, alkaline phosphatase; GGT, gamma glutamyl transferase; Bili, bilirubin; AST, aspartate transaminase; ALT, alanine transaminase; AP, alkaline phosphatase; d, day; wk, week; mo, month; ERCP, endoscopic retrograde cholangiopancreatography; OB, “oblique” bile duct; Co, Controls.
p = 0.008;
p = 0.01;
p = 0.05;
p = 0.05;
p = 0.01;
p = 0.007;
p = 0.003;
p = 0.03;
p = 0.009;
p = 0.03;
p = 0.02;
p = 0.02;
p = 0.01;
p = 0.02;
p = 0.01;
p = 0.02;
p = 0.01;
p = 0.06;
p = 0.02;
p = 0.03.
Figure 2Angle α correlates with the common bile duct diameter.
The angle α and the common bile duct (CBD) diameter of all subjects with oblique common bile duct syndrome were plotted on the y and x axes, respectively. Note that both variables display a significant negative correlation (r = −0.29, p = 0.003).
Post-ERCP events.
| “Oblique” CBD | Controls | |
| “Early” ERCP (n), yes/no | 45/58 | 28/75 |
| Multiple “early” ERCP (n), yes/no | 14/89 | 3/100 |
| Post-ERCP pancreatitis (n), yes/no | 3/100 | 4/100 |
| Subjects requiring “late” ERCP (n), yes/no | 17/74 | 8/84 |
| Total “late” ERCPs needed | 38 | 12 |
“Early” and “late” ERCP was termed an endoscopic retrograde cholangiopancreatography, which occurred within or at least a month after the previous procedure, respectively. Multiple “early” ERCPs refers to the need for at least two “early” ERCPs in one patient. A median follow-up was four years in both groups. CBD: common bile duct.
p = 0.01;
p = 0.005;
p<0.05.